In this issue:
Left-sided breast cancer: more aggressive and outcomes worse
Racial differences in early-stage, hormone receptor+ breast cancer
Supine breast RT increases skin effects in women with a large breast size
Adding denosumab to nab-paclitaxel as neoadjuvant therapy in primary breast cancer
ctDNA and late recurrence in highrisk hormone receptor+, HER2–breast cancer
Survival after breast cancer during pregnancy or after assisted reproduction
Preventing TAPS with etoricoxib in breast cancer
Venetoclax + fulvestrant in oestrogen receptor+ metastatic breast cancer after CDK-4/6 inhibitors
Abemaciclib ±tamoxifen in endocrine-refractory hormone receptor+, HER2– metastatic breast cancer
Nivolumab-bevacizumab-paclitaxel for HER2– metastatic breast cancer
Please login below to download this issue (PDF)